Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-21

Study Completion Date

2021-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase 2b clinical trial to evaluate the safety and efficacy of intranasal application of GX-03 as a treatment and prevention for COVID-19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Nasal Treatment for COVID-19

NCT05799521

COVID-19 Healthy

RECRUITING PHASE2

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection

NCT05109611

SARS-CoV-2 Infection

TERMINATED PHASE3

A Randomized Controlled Clinical Trial on the Use of Saline Nasal Irrigations to Eradicate Localized Nasal Infection by SARS-CoV-2

NCT05458336

Symptoms and Signs

COMPLETED NA

A Study to Determine the Tolerability of Intranasal LMN-301

NCT06030414

COVID-19

COMPLETED PHASE1

Intranasal Lavage With Hypochlorous Acid Safely Reduces the Symptoms in the Ambulatory Patient With COVID-19.

NCT05950295

COVID-19

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phase 2b clinical trial to evaluate the safety and efficacy of intranasal application of GX-03 as a treatment and prevention for COVID-19. Patients hospitalized with a diagnosis of mild to moderate COVID-19 will be evaluated for a period of five days. Participating health care providers will be evaluated for a period of ten days. Swab samples will be collected from the right and left anterior nostrils at the beginning of the study, as well as three times per day in the treatment arm for five days. Swab samples will be collected from the right and left anterior nostrils at the beginning and end of the prevention arm. Samples will be subjected to biomolecular tests and viral cultures to assess positivity and disease progression. Safety will be evaluated through standard measures of erythema and edema in the nasal mucosa.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Two part study with four total arms. Parts: Health care providers and CV-19 infected patients. Arms: Interventional and placebo in each of the two groups.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment of hospitalized patients with laboratory-confirmed COVID-19

Hospitalized patients with laboratory-confirmed COVID-19 using GX-03 administered intranasally TID for 5 days.

Group Type EXPERIMENTAL

GX-03

Intervention Type DRUG

Same dosage used in Bactroban Nasal studies.

Placebo Treatment of hospitalized patients with laboratory-confirmed COVID-19

Hospitalized patients with laboratory-confirmed COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 5 days.

Group Type PLACEBO_COMPARATOR

Petrolatum ointment

Intervention Type DRUG

Viscous ointment similar in form to study drug.

Prevention of SARS-COV-2 in Health Care Providers

Health care providers with laboratory-confirmed negative COVID-19 using GX-03 administered intranasally TID for 10 days.

Group Type EXPERIMENTAL

GX-03

Intervention Type DRUG

Same dosage used in Bactroban Nasal studies.

Placebo Prevention of SARS-COV-2 in Health Care Providers

Health care providers with laboratory-confirmed negative COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 10 days.

Group Type PLACEBO_COMPARATOR

Petrolatum ointment

Intervention Type DRUG

Viscous ointment similar in form to study drug.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GX-03

Same dosage used in Bactroban Nasal studies.

Intervention Type DRUG

Petrolatum ointment

Viscous ointment similar in form to study drug.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hexagen Antimicrobial Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Patients aged 18-65 hospitalized with SARS-CoV-2, diagnosed by a positive nasal or nasopharyngeal swab

2\. Men or women who are not pregnant, not breastfeeding, postmenopausal, naturally or surgically sterile, or who agree to use effective contraception during the course of the study. A postmenopausal patient is defined as at least 12 12 months of natural spontaneous amenorrhea or at least 6 weeks after surgical menopause (bilateral oophorectomy).

3\. Women of childbearing age who use one of the following acceptable contraceptive methods can be included in the study:

Surgical sterilization (hysterectomy and/or bilateral oophorectomy);

Surgical sterilization (surgical bilateral tubal ligation at least 6 weeks prior to screening); Intrauterine device (IUD) placed at least 3 months prior to detection; Abstinence (not having heterosexual sex);

Barrier method (condom or diaphragm) with spermicide for at least 14 days before selection and until completion of the study;

Stable hormonal contraceptive for at least 3 months prior to selection and until completion of the study

4\. Patients capable of understanding and providing signed informed consent.

Exclusion Criteria

1. SARS-CoV-2 positive patients on a ventilator.
2. Patients with any open wounds, injuries, inflammation, erythema, or infection (other than COVID-19) affecting the nasal passages, nose, upper lip, and the area of skin around the nose, including herpes simplex lesions.
3. Patients with a history of abnormal bleeding, bruising, frequent nosebleeds, or those diagnosed with von Willebrand disease.
4. Patients with nasal polyps or significant anatomical nasal abnormalities.
5. Patients with a history of nasal surgery, including cauterization, in the last 6 months.
6. Patients who currently have or have ever had a nose or septum piercing
7. Patients treated with antiviral medications in the past 7 days
8. Known allergy or history of significant adverse reactions to benzalkonium chloride or related compounds, or to any of the excipients.
9. Known or suspected pregnancy, pregnancy planned during the study period, or breastfeeding.
10. Clinically significant mental illness (to be determined by the investigator)
11. Recent history of (last 12 months) or strong potential for alcohol or substance abuse. Alcohol abuse will be defined as \>14 drinks per week (1 drink = 12 oz of beer, 5.0 oz of wine, or 1.5 oz of distilled spirits)
12. Exposure to any agents being researched within 30 days prior to admission to the study.
13. Prior enrollment in this study
14. If the patient has a condition that the investigator believes would interfere with their ability to give informed consent or comply with study instructions, or that could confuse the interpretation of study results or put the patient at undue risk.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No